A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...

Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

In an era where the conversation around weight loss is often dominated by the latest injectable medications, many might wonder if the more established tools, like bariatric surgery, still hold a place ...

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the ...

Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants ...

The photos, shared on Obama’s social media, show her confidently posing in a dark gray V-neck tee and distressed blue jeans, her toned arms and taut stomach on full display. Behind-the-scenes footage ...

Yet when it comes to producing the next generation of breakthrough medicines, US drugmakers and their patients appear poised to grow more, not less, dependent on Chinese innovation ...

Open enrollment runs from October 15 through December 7, giving beneficiaries a window in which to review options, including ...

Lizzo also reflected on how her coping mechanisms changed during that time. She admitted that the old version of herself ...

Doctronic reports that while Ozempic and similar GLP-1s aren’t physically addictive, psychological dependence may occur.

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.